Globally COVID-19 has already infected over 23 million people and over 814,000 people have passed away. Many countries have limited the mobility of their residents and are looking for ways to increase testing options to contain the virus and open their country. To assist in this effort, Agena Bioscience has developed a genotyping panel for the detection of the SARS-CoV-2 virus on the MassARRAY® System. This panel provides a robust option to test for the presence of SARS- CoV-2 virus in human samples. The single well panel utilizes RNA extraction and a one-step RT-PCR reaction to reverse transcribe viral RNA into cDNA and amplify the nucleic acid material in the same reaction. This biochemistry is shown to work robustly with an input containing as few as 0.3-0.4 genome copy number equivalents (GCE) of the SARS-CoV-2 virus per μl (300-400 GCE/ml) of matrix tested. The high-throughput MassARRAY® System enables laboratories to process up to 6,122 samples per day with a single instrument. The panel has been tested with the 96 and 384 CPM as well as with the RS1000 spotting device. This case study describes the iPLEX®-based SARS-CoV-2 panel being a sensitive method to reliable be used for sample pooling strategy to fight the COVID-19 pandemic. The pooling concept FACT, or Frankfurt adjusted COVID-19 testing, demonstrated excellent performance to identify a single positive sample in pools of 5, 10 and 20 samples (Schmidt et al., 2020, Hanel & Thurner, 2020). This pooling strategy will help to meet the high demand for testing in the mass coronavirus screening programs needed in the early identification and isolation of asymptomatic individuals…